AUPH vs. PCVX, CYTK, MRUS, KRYS, MTSR, RNA, AKRO, ADMA, SRRK, and ZLAB
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Vaxcyte (PCVX), Cytokinetics (CYTK), Merus (MRUS), Krystal Biotech (KRYS), Metsera (MTSR), Avidity Biosciences (RNA), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Scholar Rock (SRRK), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.
Aurinia Pharmaceuticals vs. Its Competitors
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Aurinia Pharmaceuticals presently has a consensus price target of $11.50, suggesting a potential upside of 26.79%. Vaxcyte has a consensus price target of $136.50, suggesting a potential upside of 276.66%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Aurinia Pharmaceuticals.
In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Vaxcyte. MarketBeat recorded 5 mentions for Aurinia Pharmaceuticals and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.66 beat Aurinia Pharmaceuticals' score of 0.93 indicating that Vaxcyte is being referred to more favorably in the news media.
Aurinia Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Aurinia Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
Aurinia Pharmaceuticals has a net margin of 16.11% compared to Vaxcyte's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 14.27% beat Vaxcyte's return on equity.
Summary
Aurinia Pharmaceuticals beats Vaxcyte on 9 of the 16 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AUPH) was last updated on 7/24/2025 by MarketBeat.com Staff
